ANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 7,312 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 7,312 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $75.50, for a total transaction of $552,056.00. Following the completion of the sale, the chief financial officer owned 185,543 shares of the company’s stock, valued at $14,008,496.50. This trade represents a 3.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

ANI Pharmaceuticals Trading Down 1.2%

NASDAQ:ANIP traded down $0.93 during trading hours on Thursday, reaching $75.60. 314,015 shares of the stock were exchanged, compared to its average volume of 458,954. ANI Pharmaceuticals, Inc. has a twelve month low of $56.71 and a twelve month high of $99.50. The business has a 50-day moving average of $79.92 and a two-hundred day moving average of $86.11. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of 22.50 and a beta of 0.52. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after acquiring an additional 27,598 shares during the last quarter. Global Alpha Capital Management Ltd. raised its holdings in ANI Pharmaceuticals by 17.2% during the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock worth $56,251,000 after purchasing an additional 126,500 shares in the last quarter. State Street Corp lifted its position in shares of ANI Pharmaceuticals by 2.2% during the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after buying an additional 15,496 shares during the last quarter. UBS Group AG boosted its holdings in shares of ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares in the last quarter. Finally, Tang Capital Management LLC grew its position in shares of ANI Pharmaceuticals by 51.6% in the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock valued at $38,005,000 after buying an additional 163,937 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals News Summary

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Analyst support remains strong — Guggenheim has reiterated/maintained a buy stance and has previously raised its target (recent coverage keeps favorable analyst attention, supporting longer-term demand). Guggenheim Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)
• Positive Sentiment: Reported insider buy: a Benzinga item flags an SVP & CFO purchase of roughly $1.7M of ANIP stock — insider buying can be a positive signal about management’s view of valuation. SVP & CFO At ANI Pharmaceuticals Buys $1.72M of Stock
• Neutral Sentiment: Short interest readings in recent reports show 0 shares (figures include NaN/inconsistent values and days-to-cover of 0.0), suggesting reporting oddities rather than a meaningful short-squeeze risk at present.
• Negative Sentiment: Material insider selling by the CFO — Stephen P. Carey sold 7,312 shares at an average of $75.50 (disclosed via SEC filing). While the CFO still holds a large stake, the sale reduces insider position and can pressure sentiment. CFO Form 4 (SEC)
• Negative Sentiment: Other insider sales: SVP Ori Gutwerg sold 2,060 shares at ~$76.50 (SEC filing) and insider Christopher Mutz sold 417 shares at $74 (plus a prior sale of 5,323 shares on Feb 20). Multiple near-term insider sales can weigh on near-term sentiment. Ori Gutwerg Form 4 (SEC) InsiderTrades: Christopher Mutz sale

Wall Street Analyst Weigh In

ANIP has been the topic of a number of recent research reports. Barclays assumed coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target on the stock. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Guggenheim increased their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $103.43.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.